Abstract | AIM: METHODS AND RESULTS: A multi-state, cohort, Markov model was developed to simulate the disease course of ATTR-CM throughout a lifetime. For survival extrapolation, survival curves were fitted by treatment arm and New York Heart Association (NYHA) Class I/II (68% of patients) and NYHA Class III (32% of patients) cohorts using the individual patient-level data from both the ATTR-ACT and the corresponding long-term extension study. Univariate and multivariate sensitivity analyses were conducted. The predicted mean survival for the total population (NYHA Class I/II + III) was 6.73 years for tafamidis and 2.85 years for the standard of care (SoC), resulting in an incremental mean survival of 3.88 years [95% confidence interval (CI) 1.32-5.66]. Of the 6.73 life-years, patients on tafamidis spend, on average, 4.82 years in NYHA Class I/II, while patients on SoC spend an average of 1.60 life-years in these classes. The combination of longer survival in lower NYHA classes produced a QALY gain of 5.39 for tafamidis and 2.11 for SoC, resulting in 3.29 incremental QALYs (95% CI 1.21-4.74) in favour of tafamidis. CONCLUSION: Based on the disease simulation model results, tafamidis is expected to more than double the life expectancy and QALYs of ATTR-CM patients compared to SoC. Longer-term follow-up data from the ATTR-ACT extension study will further inform these findings. CLINICAL TRIALS.GOV IDENTIFIER: NCT01994889 (date of registration: 26 November 2013).
|
Authors | Mark H Rozenbaum, Andrea Garcia, Daniel Grima, Diana Tran, Rahul Bhambri, Michelle Stewart, Benjamin Li, Bart Heeg, Maarten Postma, Ahmad Masri |
Journal | European heart journal. Quality of care & clinical outcomes
(Eur Heart J Qual Care Clin Outcomes)
Vol. 8
Issue 5
Pg. 529-538
(08 17 2022)
ISSN: 2058-1742 [Electronic] England |
PMID | 33895806
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology. |
Chemical References |
- Benzoxazoles
- Prealbumin
- tafamidis
|
Topics |
- Amyloid Neuropathies, Familial
(complications, drug therapy)
- Benzoxazoles
(therapeutic use)
- Cardiomyopathies
(complications, drug therapy)
- Humans
- Prealbumin
(therapeutic use)
|